Abstracts tagged "Uric Acid, Urate"

Abstract Number: L05 • ACR Convergence 2021
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
Robert Terkeltaub¹, JuneSik Mune², Jieun Lee³ and Kenneth Saag⁴, ¹VA/UCSD, San Diego, CA, ²LG Chem, Ltd., Seoul, ³LG Chem, Ltd., Seoul, South Korea, ⁴The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of…
Abstract Number: L06 • ACR Convergence 2021
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Kazuki Yoshida, Jun Liu, Daniel Solomon, Robert J Glynn and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…
Abstract Number: 0673 • ACR Convergence 2021
The Impact of Allopurinol on Blood Pressure and Renal Outcome in Gout Patients: A Retrospective Study
Aniqa Faraz¹, Sabeeh Islam², Joseph Grisanti³ and Shumaila Iqbal⁴, ¹University at Buffalo-CHS Sisters of Charity, Grand Island, NY, ²Brigham and Women's Hospital Cardiology, Boston, MA, ³Buffalo Rheumatology & Medicine, Orchard Park, NY, ⁴University of Cincinnati, Cincinnati, OH
Background/Purpose: The relationship between change in serum uric acid level and progression of chronic kidney disease and hypertension is still conflicting. In this study, we…
Abstract Number: 1133 • ACR Convergence 2021
The Relation of Serum Urate to Radiographic Knee Osteoarthritis in 2 Cohorts: The ELSA-Brasil MSK and the Original Cohort of the Framingham Heart Study
Ana Beatriz Vargas-Santos¹, Tuhina Neogi², Luciana Machado³, Isabela Beseñor⁴, Luciana Costa-Silva⁵, David Felson⁶, Sandhi Barreto⁷ and Rosa Telles⁸, ¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Boston University School of Medicine, Boston, MA, ³Clinical Hospital, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ⁴Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Instituto Hermes Pardini. Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ⁶Boston University, Boston, MA, ⁷Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ⁸Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Background/Purpose: Hyperuricemia may contribute to the development and/or progression of knee osteoarthritis (OA), based on increased inflammation associated with elevated serum urate (SU). Because hyperuricemia…
Abstract Number: 1566 • ACR Convergence 2021
Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery
Rachael Flood, Colm Kirby, David Kane and Ronan Mullan, Tallaght University Hospital, Dublin, Ireland
Background/Purpose: Vascular endothelial cells line the entire circulatory system, these cells have very distinct and unique functions that are paramount to vascular biology. Hyperuricemia has…
Abstract Number: 1568 • ACR Convergence 2021
AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment
zancong shen¹, Elizabeth Polvent², vijay hingorani³, Rongzi Yan⁴, Shunqi Yan⁵ and Litain Yeh⁶, ¹Arthrosi Therapeutics, Inc., San Diego, CA, ²Arthrosi Therapeutics, Inc., Roseville, CA, ³Vanguard Healthsciences, Inc., San Diego, CA, ⁴Arthrosi Therapeutics, Inc, Irvine, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout.…
Abstract Number: 1569 • ACR Convergence 2021
Effect of Elevated Serum Urate on Kidney Function: Analysis of a Randomized Controlled Trial of Inosine Supplementation
Nicola Dalbeth¹, Borislav Mihov¹, Angela Stewart¹, Gregory Gamble¹, Tony Merriman², David Mount³, Lisa Stamp⁴, Ian Reid¹ and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Alabama at Birmingham, Dunedin, New Zealand, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Observational studies have reported that serum urate associates with development and progression of kidney disease. However, it is uncertain whether elevated serum urate directly…
Abstract Number: 1570 • ACR Convergence 2021
AR882, a Novel Uricosuric Agent, Exhibited Favorable Pharmacokinetic Profile and Balanced Excretion and Metabolic Pathways in a Human AME Study
Rongzi Yan¹, zancong shen², Elizabeth Polvent³, vijay hingorani⁴, Shunqi Yan⁵ and Litain Yeh⁶, ¹Arthrosi Therapeutics, Inc, Irvine, CA, ²Arthrosi Therapeutics, Inc., San Diego, CA, ³Arthrosi Therapeutics, Inc., Roseville, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: AR882, a novel uric acid transporter 1 (URAT1) inhibitor is being developed for the treatment of gout with hyperuricemia. In Phase 1 and Phase…
Abstract Number: 1572 • ACR Convergence 2021
Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia
Bilal Bengana¹, Aicha Ladjouze², Nabil Baramtane Raaf³, Chaffa Aimeur⁴, Soraya Ayoub⁵, Abdenour Boukabous⁶ and Salima Lefkir-Tafiani⁷, ¹University Hospital of Beni Messous Algiers - Rheumatology Department, Algiers, Algeria, ²Specialized hospital establishment of Benaknoune, Rheumatology, Algiers, Algeria, ³Hospital of Bitraria, Biochemistry, El Biar, Algiers, Algeria, ⁴University hospital of Mustapha Bacha, Radiology, Sidi Mhamed, Algiers, Algeria, ⁵University hospital of Beni Messous, Internal Medicine, BeniMessous, Algiers, Algeria, ⁶University Hospital of Beni Messous Algiers- Rheumatology Department, Algiers, Algeria, ⁷University Hospital of Beni Messous Algiers - Rheumatology Department, Benimessous, Algeria
Background/Purpose: Hyperuricemia is a common biological abnormality, often clinically asymptomatic. However, it can announce a gout and be linked to many diseases such as metabolic…
Abstract Number: 1895 • ACR Convergence 2021
Achievement of Target Serum Uric Acid Among Gout Patients Treated with Long-term Urate Lowering Therapy in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Nevin Hammam, Jing Li, Julia L Kay, Jinoos Yazdany and Gabriela Schmajuk, University of California San Francisco, San Francisco, CA
Background/Purpose: The American College of Rheumatology’s (ACR) 2012 guidelines for the management of gout recommend using a treat-to-target (T2T) approach to lower serum uric acid…
Abstract Number: 1897 • ACR Convergence 2021
A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout
Nicola Dalbeth¹, Anthony Doyle¹, Karen Billington¹, Gregory Gamble¹, Paul Tan¹, Kieran Latto¹, Trish Parshu Ram¹, Ravi Narang¹, Rachel Murdoch¹, David Bursill¹, Borislav Mihov¹, Lisa Stamp² and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…
Abstract Number: 1899 • ACR Convergence 2021
Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Alison Petro¹, Tuhina Neogi² and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Patients with gout have an increased risk of mortality. Current ACR guidelines for the treatment of gout recommend a treat-to-target approach with titration of…
Abstract Number: 0665 • ACR Convergence 2021
Pegloticase Treatment for Uncontrolled Gout in Kidney Transplanted Patients: Results of an On-going Multicenter, Open-Label, Efficacy and Safety Study
Abdul Abdellatif¹, Lin Zhao², Paul M. Peloso³, Katya Cherny², Brad Marder², John D. Scandling⁴ and Kenneth Saag⁵, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics plc, Deerfield, IL, ³Horizon Therapeutics plc, Gurnee, IL, ⁴Stanford Medicine, Department of Nephrology, Stanford, CA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout in kidney transplant (KT) recipients can be severe and particularly challenging to manage. Pegloticase (pegylated recombinant uricase) rapidly metabolizes urate and is a…
Abstract Number: 0661 • ACR Convergence 2020
Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease
Nick Sumpter¹, Alexa Lupi², Megan Leask³, Tony Merriman⁴, Ana Vazquez² and Richard Reynolds¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Michigan State University, East Lansing, MI, ³University of Otago, Dunedin, Otago, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Gout and hyperuricemia (HU), serum urate (SU) > 6.8 mg/dL, often present in the context of chronic kidney disease. It has long been known…
Abstract Number: 0664 • ACR Convergence 2020
Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction
Ana B. Arevalo¹, Alba Munoz², Faris Haddadin², Karan Sud², Gustavo Contreras², Shane Murray², Yousaf Ali² and Edgar Argulian², ¹Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York, NY, ²Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York
Background/Purpose: Hyperuricemia (HUC) has been shown to have an impact in the left atrium and left ventricle remodeling leading to the development of heart failure…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].